Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Acer Therapeutics Inc.a50074813ex99_1.htm





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 8-K




CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 16, 2011



OPEXA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Texas   001-33004   76-0333165

(State or other jurisdiction of incorporation)

(Commission File Number) (IRS Employer Identification No.)

2635 Technology Forest Blvd., The Woodlands, Texas

77381
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (281) 272-9331
N/A
(Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 7.01

Regulation FD Disclosure

On November 16, 2011, Opexa Therapeutics, Inc. (the “Company”) will deliver a corporate presentation at the Lazard Capital Markets 8th Annual Healthcare Conference, which will be available via webcast, using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1.  The presentation includes an overview of the Company’s ongoing clinical development program for Tovaxin®, the Company’s lead therapy for multiple sclerosis.  The attached materials have also been posted to the Investor Relations page of the Company’s website at www.opexatherapeutics.com.  The Company does not undertake to update this presentation.

Item 9.01

Financial Statements and Exhibits

(d)  Exhibits

Exhibit No.

Description

 

99.1

Opexa Therapeutics, Inc. Corporate Presentation for Lazard Capital Markets 8th Annual Healthcare Conference, held on November 16, 2011.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities under that Section, nor be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:

November 16, 2011

OPEXA THERAPEUTICS, INC.

 

 

 

 

By:

/s/ Neil K. Warma

Neil K. Warma

President & Chief Executive Officer

3

Exhibit Index

Exhibit No.

Description

 

99.1

Opexa Therapeutics, Inc. Corporate Presentation for Lazard Capital Markets 8th Annual Healthcare Conference, held on November 16, 2011